News und Analysen

The Trust for the National Mall, Humana (NYSE: HUM), and the Humana Foundation announced today that the highly-anticipated National Mall of Pickleball is returning to America’s Front Yard, the

Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, today announced the expansion of its validated science-based target (SBT) with recent approval of a new

Agilent Technologies Inc. (NYSE: A) today announced that they will introduce their latest Hybrid Multisampler and highlight the new LC Single Quadrupole Mass Spectrometers at the upcoming HPLC 2025

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI^® (encorafenib) in combination with

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% core⁽¹⁾ compared with the

Agilent Technologies Inc. (NYSE: A) today announced August Specht, Ph.D., has been named the company’s Chief Technology Officer. Specht, previously vice president of Global R&D for the

Agilent Technologies Inc. (NYSE: A) today announced the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking

Agilent Technologies Inc. (NYSE: A) today announced the latest enhancements to the Agilent 8850 Gas Chromatograph (GC), including compatibility with single and triple quadrupole mass spectrometry

The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), announced today a $50,000 contribution to advance sustained recovery efforts in Kentucky communities devastated by the most

Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of

Agilent Technologies Inc. (NYSE: A) today announced that Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, have been elected to its Board of Directors

The Humana Foundation, the philanthropic arm of Humana Inc. for the past 44 years, is proud to announce that Tiffany Benjamin, the foundation’s CEO, has been named to the inaugural TIME100

Agilent Technologies Inc. (NYSE: A) today announced that the Infinity III LC Series — the company’s latest liquid chromatography (LC) instruments — are the first Agilent instruments to receive the

Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the

Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at the Jefferies Global Healthcare Conference at

Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025.

Bernard Zovighian, chief executive officer, and

Agilent Technologies Inc. (NYSE: A) today announced release of the new Seahorse XF Flex Analyzer, a high-performance, 24-well system designed to expand real-time metabolic analysis into optimized

Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance⁽¹⁾.

EXECUTIVE COMMENTARY

Dr. Albert Bourla, Chairman and CEO of

Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care

Agilent Technologies Inc. (NYSE: A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025.

Recent Highlights

• 
  Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted¹
  


• 
  Q1 TAVR sales

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO^®) Annual Meeting, taking place May

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the